Inventor · disambiguated record
Jennifer Brogdon
Also filed as: BROGDON JENNIFER
37 granted patents·18 pending applications·559 citations·filing 2014–2025
98Inventor score
Top patents by PatentIndex Score
55 records- 0197US10174095B2Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptorNOVARTIS AG·Filed 2015·Granted Jan 8, 2019·41 cites·50 claims
- 0297US9815901B2Treatment of cancer using a CD123 chimeric antigen receptorBROGDON JENNIFER·Filed 2015·Granted Nov 14, 2017·94 cites·40 claims
- 0397US9573988B2Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cellsBROGDON JENNIFER·Filed 2014·Granted Feb 21, 2017·87 cites·94 claims
- 0496US10525083B2Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domainNOVARTIS AG·Filed 2017·Granted Jan 7, 2020·15 cites·33 claims
- 0596US10253086B2CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cellNOVARTIS AG·Filed 2016·Granted Apr 9, 2019·37 cites·35 claims
- 0696US9394368B2Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptorBROGDON JENNIFER·Filed 2014·Granted Jul 19, 2016·112 cites·38 claims
- 0795US11084880B2Anti-BCMA chimeric antigen receptorNOVARTIS AG·Filed 2018·Granted Aug 10, 2021·15 cites·24 claims
- 0895US10927184B2Treatment of cancer using humanized anti-CD19 chimeric antigen receptorNOVARTIS AG·Filed 2018·Granted Feb 23, 2021·10 cites·26 claims
- 0995US10357514B2Treatment of cancer using anti-CD19 Chimeric Antigen ReceptorUNIV PENNSYLVANIA·Filed 2015·Granted Jul 23, 2019·18 cites·45 claims
- 1095US10221245B2Treatment of cancer using humanized anti-CD19 chimeric antigen receptorNOVARTIS AG·Filed 2014·Granted Mar 5, 2019·36 cites·67 claims
- 1194US11149076B2CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cellNOVARTIS AG·Filed 2019·Granted Oct 19, 2021·9 cites·32 claims
- 1294US11026976B2Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domainNOVARTIS AG·Filed 2019·Granted Jun 8, 2021·6 cites·23 claims
- 1394US10287354B2Regulatable chimeric antigen receptorNOVARTIS AG·Filed 2014·Granted May 14, 2019·29 cites·63 claims
- 1493US11872249B2Method of treating cancer by administering immune effector cells expressing a chimeric antigen receptor comprising a CD20 binding domainNOVARTIS AG·Filed 2021·Granted Jan 16, 2024·2 cites·38 claims
- 1591US11028177B2Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cellsNOVARTIS AG·Filed 2017·Granted Jun 8, 2021·4 cites·47 claims
- 1691US10774388B2Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereofNOVARTIS AG·Filed 2015·Granted Sep 15, 2020·7 cites·31 claims
- 1789US12344657B2CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cellNOVARTIS AG·Filed 2021·Granted Jul 1, 2025·1 cites·27 claims
- 1889US10308717B2Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptorNOVARTIS AG·Filed 2016·Granted Jun 4, 2019·4 cites·9 claims
- 1988US11865167B2Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptorNOVARTIS AG·Filed 2019·Granted Jan 9, 2024·2 cites·39 claims
- 2086US11413340B2Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapyNOVARTIS AG·Filed 2016·Granted Aug 16, 2022·2 cites·32 claims
- 2185US10568947B2Treatment of cancer using a CLL-1 chimeric antigen receptorNOVARTIS AG·Filed 2015·Granted Feb 25, 2020·6 cites·38 claims
- 2283US11578130B2Regulatable chimeric antigen receptorNOVARTIS AG·Filed 2018·Granted Feb 14, 2023·1 cites·30 claims
- 2383US10703819B2Treatment of cancer using a CD123 chimeric antigen receptorNOVARTIS AG·Filed 2017·Granted Jul 7, 2020·1 cites·33 claims
- 2483US9988455B2Methods of treating cardiovascular disorders with lectin-like oxidized LDL receptor 1 antibodiesNOVARTIS AG·Filed 2016·Granted Jun 5, 2018·3 cites·28 claims
- 2582US9562101B2Lectin-like oxidized LDL receptor 1 antibodies and methods of useHELDWEIN KURT ALEX·Filed 2014·Granted Feb 7, 2017·5 cites·27 claims
- 2681US9982046B2Methods of treating cardiovascular disorders with lectin-like oxidized LDL receptor 1 antibodiesNOVARTIS AG·Filed 2016·Granted May 29, 2018·2 cites·41 claims
- 2780US12383601B2Chimeric antigen receptors and uses thereofNOVARTIS AG·Filed 2020·Granted Aug 12, 2025·1 cites·21 claims
- 2880US10662247B2Compositions and methods of use for augmented immune response and cancer therapyNOVARTIS AG·Filed 2015·Granted May 26, 2020·2 cites·23 claims
- 2980US9512222B2Lectin-like oxidized LDL receptor 1 antibodies and methods of useHELDWEIN KURT ALEX·Filed 2014·Granted Dec 6, 2016·5 cites·23 claims
- 3080US2023374105A1Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car)-expressing cellNOVARTIS AG·Filed 2023·Application pending·0 cites
- 3179USRE49847ENucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domainNOVARTIS AG·Filed 2022·Granted Feb 27, 2024·0 cites·35 claims
- 3279US11542488B2Sortase synthesized chimeric antigen receptorsNOVARTIS AG·Filed 2015·Granted Jan 3, 2023·2 cites·14 claims
- 3379US2023220090A1Treatment of cancer using a cd123 chimeric antigen receptorNOVARTIS AG·Filed 2022·Application pending·0 cites
- 3476US12186278B2Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapyNOVARTIS AG·Filed 2022·Granted Jan 7, 2025·0 cites·27 claims
- 3572US2023026049A1Regulatable chimeric antigen receptorNOVARTIS AG·Filed 2022·Application pending·0 cites
- 3670US12214037B2Treatment of cancer using humanized anti-BCMA chimeric antigen receptorUNIV PENNSYLVANIA·Filed 2021·Granted Feb 4, 2025·0 cites·16 claims
- 3770US11591404B2Treatment of cancer using a CD123 chimeric antigen receptorNOVARTIS AG·Filed 2020·Granted Feb 28, 2023·0 cites·33 claims
- 3870US2025109401A1Compositions and methods for immunooncologyNOVARTIS AG·Filed 2023·Application pending·0 cites
- 3970US2023052970A1Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptorNOVARTIS AG·Filed 2022·Application pending·0 cites
- 4066US10870698B2Nucleic acids encoding lectin-like oxidized LDL receptor 1 antibodiesNOVARTIS AG·Filed 2018·Granted Dec 22, 2020·0 cites·24 claims
- 4166US2025319179A1Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapyNOVARTIS AG·Filed 2025·Application pending·0 cites
- 4265US2020215171A1Treatment of cancer using a cll-1 chimeric antigen receptorNOVARTIS AG·Filed 2019·Application pending·0 cites
- 4364US2020339651A1Methods for b cell preconditioning in car therapyNOVARTIS AG·Filed 2019·Application pending·0 cites
- 4462US2019388471A1Treatment of cancer using anti-cd19 chimeric antigen receptorNOVARTIS AG·Filed 2019·Application pending·0 cites
- 4562US2021172020A1Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereofNOVARTIS AG·Filed 2020·Application pending·0 cites
- 4661US11851659B2Compositions and methods for immunooncologyNOVARTIS AG·Filed 2018·Granted Dec 26, 2023·0 cites·44 claims
- 4757US2021015860A1Compositions and methods of use for augmented immune response and cancer therapyNOVARTIS AG·Filed 2020·Application pending·0 cites
- 4854US11459390B2Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptorNOVARTIS AG·Filed 2016·Granted Oct 4, 2022·0 cites·21 claims
- 4954US2017274014A1Combinations of low, immune enhancing, doses of mtor inhibitors and carsBROGDON JENNIFER·Filed 2014·Application pending·0 cites
- 5051US2018334490A1Methods for b cell preconditioning in car therapyBROGDON JENNIFER·Filed 2015·Application pending·0 cites
Showing the top 50 of 55 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Jennifer Brogdon files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →